OncoMatch/Clinical Trials/NCT07007117
PHOX2B PC-CAR T Cells for Relapsed Neuroblastoma
Is NCT07007117 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies PHOX2B PC-CAR T Cells for refractory neuroblastoma.
Treatment: PHOX2B PC-CAR T Cells — This is a first in human dose escalation trial to determine the safety of administering PHOX2B PC-CAR T cells in patients with advanced, high-risk neuroblastoma.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Neuroblastoma
Demographics
Lab requirements
Kidney function
age-adjusted serum creatinine ≤1.5 ULN for age
Liver function
Total bilirubin ≤ 1.5 x ULN (exception: ≤ 3 ULN for Gilbert's Disease or liver metastases); ALT ≤ 3.0 ULN (exception: ≤ 5 x ULN for liver metastases); AST ≤ 3.0 ULN (exception: ≤ 5 x ULN for liver metastases)
Cardiac function
LVSF ≥28% or LVEF ≥ 50% confirmed by Echo, or adequate ventricular function documented by scan or cardiologist
Liver Function: Total bilirubin ≤ 1.5 x ULN (exception: ≤ 3 ULN for Gilbert's Disease or liver metastases); ALT ≤ 3.0 ULN (exception: ≤ 5 x ULN for liver metastases); AST ≤ 3.0 ULN (exception: ≤ 5 x ULN for liver metastases). Renal Function: age-adjusted serum creatinine ≤1.5 ULN for age. Cardiac Function: LVSF ≥28% or LVEF ≥ 50% confirmed by Echo, or adequate ventricular function documented by scan or cardiologist.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Children's Hospital of Philadelphia · Philadelphia, Pennsylvania
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT07007117 currently recruiting?
Yes, this trial is currently recruiting patients.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages